Xeris Pharma's Hypoglycemia Med Receives European Nod, Shares Spike

  • The European Commission has approved Xeris Pharmaceuticals Inc's (NASDAQ: XERS) Ogluo (glucagon) injection to treat severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus. Hypoglycemia (low blood sugar level) is a complication of glucose-lowering therapy.
  • Xeris will complete a further administrative step to obtain a license in Great Britain. No re-examination of clinical data by the U.K. regulatory authority is expected.
  • In the U.S., the injection is available under the Gvoke PFS and Gvoke HypoPen brand names, approved in September 2019.
  • Price Action: XERS jumps 17.6% at $7.8 in premarket trading on the last check Friday.
Loading...
Loading...
XERS Logo
XERSXeris Biopharma Holdings Inc
$4.55-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
94.77
Growth
Not Available
Quality
Not Available
Value
25.51
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...